270 related articles for article (PubMed ID: 27212247)
1. Ursodeoxycholic acid in advanced polycystic liver disease: A phase 2 multicenter randomized controlled trial.
D'Agnolo HM; Kievit W; Takkenberg RB; Riaño I; Bujanda L; Neijenhuis MK; Brunenberg EJ; Beuers U; Banales JM; Drenth JP
J Hepatol; 2016 Sep; 65(3):601-7. PubMed ID: 27212247
[TBL] [Abstract][Full Text] [Related]
2. Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease.
Munoz-Garrido P; Marin JJ; Perugorria MJ; Urribarri AD; Erice O; Sáez E; Úriz M; Sarvide S; Portu A; Concepcion AR; Romero MR; Monte MJ; Santos-Laso Á; Hijona E; Jimenez-Agüero R; Marzioni M; Beuers U; Masyuk TV; LaRusso NF; Prieto J; Bujanda L; Drenth JP; Banales JM
J Hepatol; 2015 Oct; 63(4):952-61. PubMed ID: 26044126
[TBL] [Abstract][Full Text] [Related]
3. Ursodeoxycholic Acid for Treatment of Enlarged Polycystic Liver.
Iijima T; Hoshino J; Suwabe T; Sumida K; Mise K; Kawada M; Imafuku A; Hayami N; Hiramatsu R; Hasegawa E; Sawa N; Takaichi K; Ubara Y
Ther Apher Dial; 2016 Feb; 20(1):73-8. PubMed ID: 26482029
[TBL] [Abstract][Full Text] [Related]
4. Severity in polycystic liver disease is associated with aetiology and female gender: Results of the International PLD Registry.
van Aerts RMM; Kievit W; de Jong ME; Ahn C; Bañales JM; Reiterová J; Nevens F; Drenth JPH
Liver Int; 2019 Mar; 39(3):575-582. PubMed ID: 30225933
[TBL] [Abstract][Full Text] [Related]
5. Potential effect of tolvaptan on polycystic liver disease for patients with ADPKD meeting the Japanese criteria of tolvaptan use.
Mizuno H; Sekine A; Suwabe T; Ikuma D; Yamanouchi M; Hasegawa E; Sawa N; Ubara Y; Hoshino J
PLoS One; 2022; 17(2):e0264065. PubMed ID: 35176098
[TBL] [Abstract][Full Text] [Related]
6. Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial.
Gevers TJ; Hol JC; Monshouwer R; Dekker HM; Wetzels JF; Drenth JP
Liver Int; 2015 May; 35(5):1607-14. PubMed ID: 25369108
[TBL] [Abstract][Full Text] [Related]
7. Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial.
Chrispijn M; Gevers TJ; Hol JC; Monshouwer R; Dekker HM; Drenth JP
J Hepatol; 2013 Jul; 59(1):153-9. PubMed ID: 23499726
[TBL] [Abstract][Full Text] [Related]
8. Autophagy-mediated reduction of miR-345 contributes to hepatic cystogenesis in polycystic liver disease.
Masyuk T; Masyuk A; Trussoni C; Howard B; Ding J; Huang B; LaRusso N
JHEP Rep; 2021 Oct; 3(5):100345. PubMed ID: 34568801
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of 4 Years of Octreotide Long-Acting Release Therapy in Patients With Severe Polycystic Liver Disease.
Hogan MC; Masyuk T; Bergstralh E; Li B; Kremers WK; Vaughan LE; Ihrke A; Severson AL; Irazabal MV; Glockner J; LaRusso NF; Torres VE
Mayo Clin Proc; 2015 Aug; 90(8):1030-7. PubMed ID: 26166166
[TBL] [Abstract][Full Text] [Related]
10. Long-acting somatostatin analogue treatments in autosomal dominant polycystic kidney disease and polycystic liver disease: a systematic review and meta-analysis.
Griffiths J; Mills MT; Ong AC
BMJ Open; 2020 Jan; 10(1):e032620. PubMed ID: 31924636
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Targets in Polycystic Liver Disease.
Masyuk TV; Masyuk AI; LaRusso NF
Curr Drug Targets; 2017; 18(8):950-957. PubMed ID: 25915482
[TBL] [Abstract][Full Text] [Related]
12. Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease.
van Aerts RMM; Kievit W; D'Agnolo HMA; Blijdorp CJ; Casteleijn NF; Dekker SEI; de Fijter JW; van Gastel M; Gevers TJ; van de Laarschot LFM; Lantinga MA; Losekoot M; Meijer E; Messchendorp AL; Neijenhuis MK; Pena MJ; Peters DJM; Salih M; Soonawala D; Spithoven EM; Visser FW; Wetzels JF; Zietse R; Gansevoort RT; Drenth JPH;
Gastroenterology; 2019 Aug; 157(2):481-491.e7. PubMed ID: 31022403
[TBL] [Abstract][Full Text] [Related]
13. Modelling polycystic liver disease progression using age-adjusted liver volumes and targeted mutational analysis.
Sierks D; Schönauer R; Friedrich A; Hantmann E; de Fallois J; Linder N; Fischer J; Herber A; Bergmann C; Berg T; Halbritter J
JHEP Rep; 2022 Nov; 4(11):100579. PubMed ID: 36246085
[TBL] [Abstract][Full Text] [Related]
14. Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease.
Gevers TJ; Chrispijn M; Wetzels JF; Drenth JP
BMC Nephrol; 2012 Apr; 13():17. PubMed ID: 22475206
[TBL] [Abstract][Full Text] [Related]
15. Bile Acids in Polycystic Liver Diseases: Triggers of Disease Progression and Potential Solution for Treatment.
Perugorria MJ; Labiano I; Esparza-Baquer A; Marzioni M; Marin JJ; Bujanda L; Banales JM
Dig Dis; 2017; 35(3):275-281. PubMed ID: 28249268
[TBL] [Abstract][Full Text] [Related]
16. Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease.
Pisani A; Sabbatini M; Imbriaco M; Riccio E; Rubis N; Prinster A; Perna A; Liuzzi R; Spinelli L; Santangelo M; Remuzzi G; Ruggenenti P;
Clin Gastroenterol Hepatol; 2016 Jul; 14(7):1022-1030.e4. PubMed ID: 26844873
[TBL] [Abstract][Full Text] [Related]
17. The Longitudinal Study of Liver Cysts in Patients With Autosomal Dominant Polycystic Kidney Disease and Polycystic Liver Disease.
Matsuura R; Honda K; Hamasaki Y; Doi K; Noiri E; Nangaku M
Kidney Int Rep; 2017 Jan; 2(1):60-65. PubMed ID: 29142941
[TBL] [Abstract][Full Text] [Related]
18. Clinical manifestation, epidemiology, genetic basis, potential molecular targets, and current treatment of polycystic liver disease.
Mahboobipour AA; Ala M; Safdari Lord J; Yaghoobi A
Orphanet J Rare Dis; 2024 Apr; 19(1):175. PubMed ID: 38671465
[TBL] [Abstract][Full Text] [Related]
19. Liver involvement in early autosomal-dominant polycystic kidney disease.
Hogan MC; Abebe K; Torres VE; Chapman AB; Bae KT; Tao C; Sun H; Perrone RD; Steinman TI; Braun W; Winklhofer FT; Miskulin DC; Rahbari-Oskoui F; Brosnahan G; Masoumi A; Karpov IO; Spillane S; Flessner M; Moore CG; Schrier RW
Clin Gastroenterol Hepatol; 2015 Jan; 13(1):155-64.e6. PubMed ID: 25111236
[TBL] [Abstract][Full Text] [Related]
20. Center is an important indicator for choice of invasive therapy in polycystic liver disease.
D'Agnolo HM; Kievit W; van Munster KN; van der Laan JJ; Nevens F; Drenth JP
Transpl Int; 2017 Jan; 30(1):76-82. PubMed ID: 27732751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
